-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 27, Tianyu Pharmaceutical announced that the company received the CEP certificate for rivaroxaban API issued by the European Agency for the Quality of Medicines
Rivaroxaban is an anticoagulant drug for the prevention of venous thrombosis (VTE) in adults undergoing hip or knee replacement surgery; or for the treatment of deep vein thrombosis (DVT) in adults to reduce DVT recurrence after acute DVT and risk of pulmonary embolism (PE); or in adults with nonvalvular atrial fibrillation to reduce the risk of stroke and systemic embolism
In October 2020, the company submitted a drug registration application for rivaroxaban API to EDQM and obtained a CEP certificate